ReviewJournal of tropical medicine2018
Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite.
Review in Journal of tropical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04996264 (Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes), which is not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes
Who cites it
43 citing papers in PubMed, 82 citations in OpenAlex.
- Biological Effects of Secretory Phospholipase ABulletin of experimental biology and medicine · 2026Article
- Targeting Key Enzymatic Snake Venom Proteins Using Repurposed Small Molecule Inhibitors: Emerging Adjuncts to Antivenom Therapy.International journal of molecular sciences · 2026Review
- Snake Venom Protease Detection and Inhibition in Serum.ChemMedChem · 2026Article
- Article
- Enhancing Deinagkistrodon acutus antivenom potency through acutolysin A-targeted antibody supplementation.PLoS neglected tropical diseases · 2025Article
- Preclinical evaluation of small molecule inhibitors as early intervention therapeutics against Russell's viper envenoming in India.Communications medicine · 2025Article
- Article
- Article
- Article
- Article
- Emerging Trends in Snake Venom-Loaded Nanobiosystems for Advanced Medical Applications: A Comprehensive Overview.Pharmaceutics · 2025Review
- Landscape of toxin-neutralizing therapeutics for snakebite envenoming (2015-2022): Setting the stage for an R&D agenda.PLoS neglected tropical diseases · 2024Article
- Article
- Review
- Viper Venom Phospholipase A2 Database: The Structural and Functional Anatomy of a Primary Toxin in Envenomation.Toxins · 2024Article
- Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms.Nature communications · 2023Article
- Considerations for the development of a field-based medical device for the administration of adjunctive therapies for snakebite envenoming.Toxicon: X · 2023Article
- In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell's Viper (Toxins · 2023Article
- Immunoprofiling of Equine Plasma againstTropical medicine and infectious disease · 2023Article
- Towards better antivenoms: navigating the road to new types of snakebite envenoming therapies.The journal of venomous animals and toxins including tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) recently added snakebite envenoming to the priority list of Neglected Tropical Diseases (NTD). It is thought that ~75% of mortality following snakebite occurs outside the hospital setting, making the temporal gap between a bite and antivenom administration a major therapeutic challenge. Small molecule therapeutics (SMTs) have been proposed as potential prereferral treatments for snakebite to help address this gap. Herein, we discuss the characteristics, potential uses, and development of SMTs as potential treatments for snakebite envenomation. We focus on SMTs that are secretory phospholipase A2 (sPLA
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.